BioStock Studio: Cereno’s CEO is looking forward to trial start

Gothenburg-based Cereno Scientific has made a number of preparations for the coming initiation of the phase II trial with their candidate CS1 in the rare cardiovascular disease PAH. CEO Sten R Sörensen visited BioStock’s studio to tell us more about this, the collaboration with Abbott, the coming subscription of TO1 and the expanded pipeline. Watch the interview, in Swedish, at biostock.se.

Watch the interview with Cereno Scientific’s CEO Sten R Sörensen at biostock.se:

https://www.biostock.se/en/2021/08/biostock-studio-cerenos-ceo-is-looking-forward-to-trial-start/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/